stockrow
Monday 9 November 2026
Export VNDA’s income statement to Excel — free account
Vanda Pharmaceuticals Inc.
VNDAVanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024.
- Revenue
- +24.1%
- EPS
- +1.82%
- Free cash flow
- +9.57%
- Total debt
- −16.5%
Quarter to September 2026, against a year earlier
3.82
0.23
+6.41%
Follow VNDA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 2 | 2 |
+8 more TTM periods Free account |
| (82.55%) | (77.81%) | (60.48%) | (50.93%) | ||
| (55.89%) | (53.00%) | (44.97%) | (38.51%) | ||
ROIC |
(180.19%) | (217.59%) | (121.87%) | (140.15%) | |
Return on Tangible Assets |
(317.66%) | (266.75%) | (149.87%) | (107.89%) | |
Average Days of Receivables |
96.02 | 101.00 | 95.33 | 92.18 | |
Free Cash Flow per Share |
(2.48) | (2.54) | (2.31) | (1.87) | |
Free Cash Flow |
(149.96) | (153.00) | (137.30) | (110.44) | |
Capital Expenditures |
(10.82) | (10.67) | (10.78) | (1.00) | |
| Other line items | |||||
Cash ROIC |
(43.76%) | (38.89%) | (28.20%) | (18.56%) | |
Accounts Receivable Turnover |
4.14 | 4.12 | 4.29 | 4.25 | |
Accounts Payable Turnover |
0.27 | 0.21 | 0.24 | 0.24 | |
Inventory Turnover |
8.24 | 7.02 | 7.00 | 7.29 | |
Average Days of Payables |
1,503.99 | 1,891.59 | 1,744.70 | 1,911.10 | |
Days of Inventory on Hand |
37.93 | 45.35 | 48.90 | 51.82 | |
Tax Rate |
0.61 | 0.55 | 0.60 | 0.59 | |
Research and Development Expense of Revenue |
53.22% | 54.22% | 46.83% | 50.56% | |
Selling, General and Administrative Expense of Revenue |
114.60% | 122.13% | 117.65% | 110.11% | |
Share Based Compensation of Revenue |
4.05% | 4.20% | 4.16% | 4.38% | |
Operating CF/Net income |
0.51 | 0.52 | 0.53 | 0.50 | |
Depreciation/Fixed assets |
4.46 | 4.85 | 4.98 | 4.39 | |
Capex/Depreciation |
(0.80) | (0.85) | (0.96) | (0.10) | |
Revenue per Share |
3.79 | 3.58 | 3.66 | 3.67 | |
Operating CF per Share |
(2.30) | (2.36) | (2.13) | (1.86) | |
Capex per Share |
(0.18) | (0.18) | (0.18) | (0.02) | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026